Christopher Rowland
Christopher Rowland
CRITIC
img-contested
N/A
0 reviews
PUBLIC
img-contested
N/A
0 reviews

RECENT ARTICLES

Sort by:
No Rating
Taxpayers paid to develop remdesivir but will have no say when Gilead sets the price

Taxpayers paid to develop remdesivir but will have no say when Gilead sets the price

This article was published more than 2 years agoCommentGift ShareThe drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, started as a reject, an also-ran in the search for antiviral drugs. Its path to relevance didn’t begin until Robert Jordan plucked it from mothballs.A Gilead scientist at the time, Jordan convinced the company seven years ago to let him assemble a library of 1,000 castoff molecules in a search for medicines to treat emerging viruses. Many viral illnesses threaten human health because they lack potential for...

May 26, 2020
Share
Save
Review
No Rating
Taxpayers paid to develop remdesivir but will have no say when Gilead sets price

Taxpayers paid to develop remdesivir but will have no say when Gilead sets price

This is a carousel. Use Next and Previous buttons to navigateThe drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject, an also-ran in the search for antiviral drugs. Its path to relevance did not begin until Robert Jordan cleared it.A Gilead scientist at the time, Jordan convinced the company seven years ago to let him assemble a library of 1,000 castoff molecules in a search for medicines to treat emerging viruses. Many viral illnesses threaten human health but do not attract commercial interest,...

May 26, 2020
Share
Save
Review
No Rating
FDA authorizes use of Gilead Sciences’ remdesivir for patients severely ill with covid-19

FDA authorizes use of Gilead Sciences’ remdesivir for patients severely ill with covid-19

This article was published more than 2 years agoCommentGift ShareThe Food and Drug Administration issued an emergency use authorization Friday that will allow doctors to use Gilead Sciences’ drug remdesivir to treat patients who are hospitalized with serious cases of covid-19.The limited approval allows the antiviral drug, which is administered intravenously, to be used to treat the disease in adults and children hospitalized with severe disease, which is defined as patients with low blood oxygen levels or needing oxygen therapy or a mechanical ventilator. Such an approval allows the...

May 1, 2020
Share
Save
Review
No Rating
U.S. passes 60,000 dead as hopes rise for a promising drug therapy

U.S. passes 60,000 dead as hopes rise for a promising drug therapy

This article was published more than 2 years agoCommentGift ShareThis article is free to access.Why?The Washington Post is providing this news free to all readers as a public service.Follow this story and more by U.S. deaths from covid-19 passed 60,000 on Wednesday, a figure President Trump had once projected would be the upper limit, as hopes rose for a drug treatment that the top U.S. infectious-disease expert said has shown a clear benefit in an early trial.Trump welcomed the promising early signs that an experimental antiviral drug, remdesivir, can be effective in speeding the...

April 30, 2020
Share
Save
Review
No Rating
Trump sets goal of hundreds of millions of coronavirus vaccine doses by January, but scientists doubt it

Trump sets goal of hundreds of millions of coronavirus vaccine doses by January, but scientists doubt it

This article was published more than 2 years agoCommentGift ShareThis article is free to access.Why?The Washington Post is providing this news free to all readers as a public service.Follow this story and more by President Trump formally unveiled an initiative Friday afternoon aimed at making hundreds of millions of doses of a broadly available by year’s end — a goal that many scientists say is unrealistic and could even backfire by shortchanging safety and more broadly.The Rose Garden news conference added to a week of confusing and contradictory remarks about the prospects and...

May 15, 2020
Share
Save
Review
No Rating
FDA warns about hydroxychloroquine dangers, citing serious heart issues, including death

FDA warns about hydroxychloroquine dangers, citing serious heart issues, including death

This article was published more than 2 years agoCommentGift ShareThe Food and Drug Administration warned Friday that doctors should not use the malaria drugs chloroquine and hydroxychloroquine to treat covid-19 patients outside a hospital or a clinical trial, citing reports of “serious heart rhythm problems.”The drugs have been who has called them a potential “game-changer,” even though results from clinical trials have not yet shown the drugs to be effective for covid-19, the disease caused by the coronavirus.An increasing number of , making the drugs an example of how the president’s...

April 24, 2020
Share
Save
Review
No Rating
Europe is paying less than U.S. for many coronavirus vaccines

Europe is paying less than U.S. for many coronavirus vaccines

This article was published more than 2 years agoCommentGift ShareThe European Union is paying less money than the United States for a range of coronavirus vaccines, including the Pfizer-BioNTech inoculation being rolled out across the country, according to a Washington Post comparison of the breakdowns.The costs to the E.U. had been confidential until a Belgian official tweeted — and then deleted — a list late Thursday.Comparing that list with U.S. calculations by Bernstein Research, an analysis and investment firm, it appears that the 27-nation union has a 24 percent discount on the...

December 18, 2020
Share
Save
Review
No Rating
Trump’s Operation Warp Speed promised a flood of covid vaccines. Instead, states are expecting a trickle.

Trump’s Operation Warp Speed promised a flood of covid vaccines. Instead, states are expecting a trickle.

This article was published more than 2 years agoCommentGift ShareFederal officials have slashed the amount of coronavirus vaccine they plan to ship to states in December because of constraints on supply, sending local officials into a scramble to adjust vaccination plans and highlighting how of a vast stockpile before the end of 2020 have fallen short.Instead of the delivery of doses of vaccine immediately after emergency-use approval and before the end of 2020 as the Trump administration had originally promised, current plans call for availability of around a tenth of that, or 35 to...

December 5, 2020
Share
Save
Review
No Rating
Gilead sets price of coronavirus drug remdesivir at $3,120 as Trump administration secures supply for 500,000 patients

Gilead sets price of coronavirus drug remdesivir at $3,120 as Trump administration secures supply for 500,000 patients

This article was published more than 2 years agoCommentGift ShareGilead Sciences, the maker of the first covid-19 treatment found to have worked in clinical trials, remdesivir, said Monday it will charge U.S. hospitals $3,120 for the typical patient with private insurance.Soon after the announcement, the Trump administration said it had secured nearly all of the company’s supply of the drug for use in U.S. hospitals through September, with a contract for 500,000 treatment courses, which it will make available to hospitals at Gilead’s price.Other developed countries will pay 25 percent...

June 29, 2020
Share
Save
Review
No Rating
Senior-care referral site ‘A Place for Mom’ stays mum on neglect

Senior-care referral site ‘A Place for Mom’ stays mum on neglect

When families search the internet for senior-care homes, they inevitably come upon A Place for Mom. The site says it helps 700,000 people every year.It calls itself the nation’s leading “trusted advisory service,” but in reality A Place for Mom is a referral service that is paid large fees by assisted-living facilities and does not independently assess their records. More than a third of its most highly recommended facilities in 28 states were cited for neglect or substandard care in the past two years, many of them repeatedly, according to a Washington Post review of inspection reports.

  • Total 22 items
  • 1
  • 2
  • 3
OUTLETS
washingtonpost.com

washingtonpost.com

CRITIC
img-trusted
88%
PUBLIC
img-trusted
68%
chron.com

chron.com

CRITIC
img-contested
N/A
PUBLIC
img-contested
N/A